Clinical

Videos

Tian Zhang , MD, discusses the adaptive phase 3 PDIGREE study comparing immunotherapy only versus immunotherapy/TKI regimens in patients with advanced kidney cancer.

Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.

Dr. Stewart assesses novel renal cancer treatment

“The concept behind the NAXIVA trial was to treat these patients with pre-surgical neoadjuvant targeted therapy with a means of downstaging that venous tumor thrombus, reducing the extent of it to try and make the surgery less morbid to the patient and to potentially improve survival,” says Grant Stewart, MD.

Dr. Stewart discusses study of neoadjuvant axitinib in renal cell carcinoma 

Articles

The combination demonstrated encouraging clinical activity in patients with both clear cell and non–clear cell renal cell carcinoma.  

Combo of cabozantinib plus atezolizumab active across kidney cancer subtypes

Michael S. Cookson, MD, previews the 2021 AUA Annual Meeting, with a focus on prostate, bladder, and kidney cancer. His in-depth analysis covers the plenary sessions, late-breaking abstracts, and other abstracts of interest.

2021 AUA Annual Meeting Preview: Prostate, Bladder, and Kidney Cancer

 is an associate professor of medicine in the Division of Hematology/Oncology, Department of Internal Medicine at Mayo Clinic, Phoenix, Arizona.

Patients may require specific diagnostic, surveillance, and therapeutic management.

Recognizing hereditary syndromes in renal cell carcinoma

The FDA is scheduled to decide on the application for adjuvant pembrolizumab in renal cell carcinoma on or before December 10, 2021.

Adjuvant pembrolizumab data published in NEJM as FDA weighs kidney cancer approval 

Ventana MMR RxDx Panel is a qualitative immunohistochemistry test that assesses a panel of MMR proteins to help guide clinicians in their  treatment decisions. 

FDA approves dostarlimab companion diagnostic for use across dMMR solid tumors 

The approval provides urologists with another tool for the treatment of patients with genitourinary cancers and underscores the rapidly growing significance of genetic testing in the field of urology.

FDA grants tumor-agnostic approval to immunotherapy dostarlimab

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma.